The Medical Advisor

Low-dose naltrexone (LDN) is generating buzz as a potential treatment for a range of conditions, from chronic pain to autoimmune disorders, offering new hope for patients with difficult-to-manage symptoms. While hailed for its symptom relief, some health experts warn that LDN may not tackle the underlying causes of disease. The question remains: Is this affordable, underutilized drug a breakthrough or merely a temporary fix? A Lifeline Linda Elsgood felt unstoppable. A mother of two and full-time bank manager, she balanced work and family with ease. “I was Wonder Woman. I could do anything,” she told The Epoch Times. But when both her parents fell ill, the stress of caregiving began to take its toll. Soon after, Elsgood began experiencing troubling symptoms: numbness in her leg and face, extreme fatigue, and vision issues. In 2000, she was diagnosed with relapsing-remitting multiple sclerosis (MS). By 2003, the disease had progressed to secondary progressive MS, and her doctors informe...

Cancer drug resistance significantly reduces the effectiveness of current anticancer treatments. This highlights the need for developing new multi-targeting drugs that are more cost-effective, have fewer side effects, and remain effective against cancer. Drug repurposing offers a promising solution over expensive targeted therapies. Repurposing Mebendazole: it’s already been given to millions of people at high doses with a very good safety record, repurposing it for cancer is much faster and cheaper than inventing a brand-new drug. How MEBENDAZOLE Fights Cancer and Cancer Drug Resistance. This review breaks down six key ways Mebendazole attacks cancer. Mebendazole hits all of them at the same time, which is why it may overcome resistance better than single-target drugs: 1. Disrupts the cancer cell’s skeleton (microtubules) MBZ binds to the same spot on tubulin that the cancer drug colchicine uses. This stops cancer cells from properly dividing (they get stuck in the G2/M pha...